BAY98751 (Y65-110)

PreclinicalSmall molecule

Bayer

BAY98751 (Y65-110) is one of 11 small molecule programs targeting TIA. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TIACompleted

TIAPreclinical

Completed

Competition

Competitive Landscape

14 competitors in TIA

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

1 2

Calquence

AstraZeneca

Phase 2

1 3

Venclexta

AbbVie

Phase 2

1 4

Gazyva

Roche

Phase 2

1 5

Tegafur-Gimeracil-Oteracil

NNational Taiwan University Hospital

Phase 3

1 6

Sequential

PPeking Union Medical College Hospital

Phase 3

1 7

BAY 987519

Bayer

Preclinical

2 8

Apelin

UUniversity of Edinburgh

Preclinical

1 9

Standard SPF 4 Sunscreen

Bayer

Preclinical

2 10

Menopur

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TIA1 trial

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Completed· Bayer logo

Bayer·N/A·NCT02869113·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BAY98751 (Y65-110). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAY98751 (Y65-110) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAY98751 (Y65-110). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

BAY98751 (Y65-110)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TIA1 trial

References

Drug Info

Quick Facts

Related News